September 2, 2024 01:00 AM EDTUpdated September 3, 06:44 AM

Sanofi’s BTK inhibitor goes 1-for-3 in key MS trials, slows disability progression

Max Bayer

Pharma Reporter

The potential of Sanofi’s closely-watched BTK inhibitor in multiple sclerosis is coming into clearer view amid plans to narrow the focus of the French company’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi’s BTK inhibitor goes 1-for-3 in key MS trials, slows disability progression

Max Bayer

Pharma Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Sanofi’s BTK in­hibitor goes 1-for-3 in key MS tri­als, slows dis­abil­i­ty pro­gres­sion

Max Bayer

Pharma Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Sanofi’s BTK inhibitor goes 1-for-3 in key MS trials, slows disability progression

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?